CANDICE COLEMAN: Open Payments
NPI 1073912366 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,036 in 27 payments from 9 companies in 2025. Trend: 2023 $153 · 2024 $626 · 2025 $1,036
Food & beverage: $1,036
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 10 | $262 |
| AstraZeneca Pharmaceuticals LP | 2 | $221 |
| Abbott Laboratories | 2 | $192 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $135 |
| ABBVIE INC. | 4 | $68 |
| Novo Nordisk Inc | 3 | $63 |
| PFIZER INC. | 2 | $49 |
| Merck Sharp & Dohme LLC | 1 | $29 |
| Boston Scientific Corporation | 1 | $18 |
Products named: BREZTRI, FREESTYLE LIBRE 3, JARDIANCE, Biktarvy, VRAYLAR, PREVNAR 20, Ozempic, PIFELTRO.
Industry payments across MS — which companies pay providers there.
